|Bid||10.47 x 900|
|Ask||10.70 x 21500|
|Day's range||10.28 - 10.74|
|52-week range||9.66 - 15.60|
|Beta (5Y monthly)||1.28|
|PE ratio (TTM)||76.50|
|Forward dividend & yield||0.48 (4.48%)|
|Ex-dividend date||23 May 2022|
|1y target est||N/A|
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Downturns are a great time to load up on high-quality dividend stocks. Falling share prices pump up dividend yields, and that means you'll get more bang for your buck in the long run, assuming that the stocks you buy eventually return to growth. Viatris (NASDAQ: VTRS) manufactures a smorgasbord of common generic drugs and it also produces reputable brands like EpiPens, Viagra, and Lipitor.
Shares of Viatris (NASDAQ: VTRS), a biopharmaceutical company known for its branded, generic, and biosimilar therapies, saw its shares rise 18.8% in May, according to data provided by S&P Global Market Intelligence.